We propose that a secondary consequence of reduced ALOX5 expression in lung adenocarcinoma is that the production of SPMs such as RvD1 and AT-RvD1 will also be reduced in the tumour microenvironment. The gene discussed is ALOX5; the disease is neoplasm.